KR102408288B1 - 간내 담즙 정체성 질환의 치료 - Google Patents

간내 담즙 정체성 질환의 치료 Download PDF

Info

Publication number
KR102408288B1
KR102408288B1 KR1020187037704A KR20187037704A KR102408288B1 KR 102408288 B1 KR102408288 B1 KR 102408288B1 KR 1020187037704 A KR1020187037704 A KR 1020187037704A KR 20187037704 A KR20187037704 A KR 20187037704A KR 102408288 B1 KR102408288 B1 KR 102408288B1
Authority
KR
South Korea
Prior art keywords
celadelfar
disease
liver
cholestasis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187037704A
Other languages
English (en)
Korean (ko)
Other versions
KR20190015363A (ko
Inventor
뽈 부드
찰스 에이 맥위어터
Original Assignee
사이머베이 쎄라퓨틱스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이머베이 쎄라퓨틱스, 인코퍼레이티드 filed Critical 사이머베이 쎄라퓨틱스, 인코퍼레이티드
Publication of KR20190015363A publication Critical patent/KR20190015363A/ko
Application granted granted Critical
Publication of KR102408288B1 publication Critical patent/KR102408288B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187037704A 2016-05-31 2017-04-26 간내 담즙 정체성 질환의 치료 Active KR102408288B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
US62/343,688 2016-05-31
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (2)

Publication Number Publication Date
KR20190015363A KR20190015363A (ko) 2019-02-13
KR102408288B1 true KR102408288B1 (ko) 2022-06-10

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187037704A Active KR102408288B1 (ko) 2016-05-31 2017-04-26 간내 담즙 정체성 질환의 치료

Country Status (27)

Country Link
US (5) US10272058B2 (OSRAM)
EP (1) EP3463328B1 (OSRAM)
JP (1) JP7079735B2 (OSRAM)
KR (1) KR102408288B1 (OSRAM)
CN (1) CN109195594A (OSRAM)
AU (1) AU2017274293B2 (OSRAM)
BR (1) BR112018074147A2 (OSRAM)
CA (1) CA3024155C (OSRAM)
CY (1) CY1125465T1 (OSRAM)
DK (1) DK3463328T3 (OSRAM)
ES (1) ES2921230T3 (OSRAM)
HR (1) HRP20220903T1 (OSRAM)
HU (1) HUE059838T2 (OSRAM)
IL (1) IL263372B2 (OSRAM)
LT (1) LT3463328T (OSRAM)
MX (1) MX390417B (OSRAM)
NZ (1) NZ748721A (OSRAM)
PL (1) PL3463328T3 (OSRAM)
PT (1) PT3463328T (OSRAM)
RS (1) RS63345B1 (OSRAM)
RU (1) RU2765460C2 (OSRAM)
SG (1) SG11201810123SA (OSRAM)
SI (1) SI3463328T1 (OSRAM)
SM (1) SMT202200471T1 (OSRAM)
UA (1) UA122719C2 (OSRAM)
WO (1) WO2017209865A1 (OSRAM)
ZA (1) ZA201808360B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
HUE041733T2 (hu) 2014-03-20 2019-05-28 Cymabay Therapeutics Inc Intrahepatikus kolesztázisos betegségek kezelése
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
BR112021009038A2 (pt) * 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. tratamento combinado de nafld e nash
SI4225291T1 (sl) * 2021-02-01 2024-07-31 CymaBay Therapeutics, Inc., Zdravljenje holangiopatij s seladelparjem

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143178A1 (en) * 2014-03-20 2015-09-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
CA2749312A1 (en) 1996-02-14 1997-08-21 Novartis Ag Sugar-modified gapped oligonucleotides
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
CA2539446C (en) 2003-09-19 2013-12-03 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
DK1725234T4 (en) 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
MX2011004077A (es) 2008-10-17 2011-08-17 Metabolex Inc Metodos para reducir particulas de ldl densas, pequeñas.
NZ720946A (en) * 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2011123401A1 (en) 2010-03-30 2011-10-06 Novartis Ag Uses of dgat1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2015077154A1 (en) 2013-11-20 2015-05-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2015157697A1 (en) 2014-04-11 2015-10-15 Cymabay Therapeutics, Inc. Treatment of nafld and nash
CN106470675A (zh) 2014-06-26 2017-03-01 西玛贝医药公司 严重高甘油三酯血症的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
AU2018342323B2 (en) 2017-09-26 2021-09-23 Cymabay Therapeutics, Inc. Treatment of cholestatic pruritus
CA3118965A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
BR112021009038A2 (pt) 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. tratamento combinado de nafld e nash

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143178A1 (en) * 2014-03-20 2015-09-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Clin Endocrinol Metab. 96, 2889~2897, 2011*

Also Published As

Publication number Publication date
MX2018014915A (es) 2019-04-24
US20170340589A1 (en) 2017-11-30
RU2018146504A3 (OSRAM) 2020-07-27
DK3463328T3 (da) 2022-07-04
MX390417B (es) 2025-03-20
RU2765460C2 (ru) 2022-01-31
ES2921230T3 (es) 2022-08-22
AU2017274293B2 (en) 2022-03-31
RU2018146504A (ru) 2020-07-09
US20210000774A1 (en) 2021-01-07
PL3463328T3 (pl) 2022-10-03
US11596614B2 (en) 2023-03-07
HUE059838T2 (hu) 2023-01-28
SMT202200471T1 (it) 2023-01-13
UA122719C2 (uk) 2020-12-28
LT3463328T (lt) 2022-08-10
US20190255004A1 (en) 2019-08-22
EP3463328B1 (en) 2022-06-15
CY1125465T1 (el) 2025-05-09
US10272058B2 (en) 2019-04-30
EP3463328A1 (en) 2019-04-10
PT3463328T (pt) 2022-07-07
SI3463328T1 (sl) 2022-08-31
BR112018074147A2 (pt) 2019-03-06
KR20190015363A (ko) 2019-02-13
IL263372A (en) 2018-12-31
CA3024155A1 (en) 2017-12-07
US20210220305A1 (en) 2021-07-22
HRP20220903T1 (hr) 2022-10-14
US10478411B2 (en) 2019-11-19
JP2019518022A (ja) 2019-06-27
IL263372B2 (en) 2023-06-01
NZ748721A (en) 2022-04-29
ZA201808360B (en) 2020-02-26
CN109195594A (zh) 2019-01-11
US10813895B2 (en) 2020-10-27
RS63345B1 (sr) 2022-07-29
US11000494B2 (en) 2021-05-11
WO2017209865A1 (en) 2017-12-07
SG11201810123SA (en) 2018-12-28
AU2017274293A1 (en) 2018-12-13
US20200061006A1 (en) 2020-02-27
CA3024155C (en) 2023-10-10
JP7079735B2 (ja) 2022-06-02

Similar Documents

Publication Publication Date Title
US11406611B2 (en) Treatment of intrahepatic cholestatic diseases
US11596614B2 (en) Treatment of intrahepatic cholestatic diseases
US11224580B2 (en) Treatment of intrahepatic cholestatic diseases
HK1262698A1 (en) Seladelpar for the treatment of primary biliary cholangitis
HK1262698B (en) Seladelpar for the treatment of primary biliary cholangitis
HK1229212A1 (en) Treatment of intrahepatic cholestatic diseases
HK1229212B (en) Treatment of intrahepatic cholestatic diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000